X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used in the development of AG10 (acoramidis HCl). Which is being evaluated in the Phase III clinical trial studies for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 04, 2024
Details:
Under the agreement, BridgeBio grants Bayer exclusive license to commercialize acoramidis, an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of TTR, as a treatment for patients with ATTR-CM in Europe.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Licensing Agreement March 04, 2024
Details:
Through the acquisition, Bayer leverages the commercialization rights of AG10 (acoramidis) rights for European markets. It is a highly potent and selective small molecule, orally administered transthyretin stabilizer for the treatment of patients suffering from ATTR CM.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 04, 2024
Details:
AG-10 (acoramidis) is an investigational, next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin (TTR). It is being evaluated in phase 3 clinical trials for the treatment of Transthyretin Amyloid Cardiomyopathy.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
The net proceeds will be used in the anticipated launch of AG10 (acoramidis HCl) as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Owl Capital
Deal Size: $500.0 million Upfront Cash: $500.0 million
Deal Type: Financing January 18, 2024
Details:
AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
The net proceeds will fund the launch of AG10 (acoramidis), an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), and company's upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qatar Investment Authority
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 25, 2023
Details:
AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin (TTR), being investigated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
The Company intend to use the proceeds from this offering to fund clinical and pre-clinical development of company's current and future product candidates including AG10 (acoramidis), conduct research activities, and for working capital and other general corporate purposes.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Neurology Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 08, 2023
Details:
The Company intend to use the proceeds from this offering to fund clinical and pre-clinical development of company's current and future product candidates including AG10 (acoramidis), conduct research activities, and for working capital and other general corporate purposes.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Neurology Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 06, 2023
Details:
NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout study. At Month 30, median change from baseline was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2022
Details:
AG10 (acoramidis) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Using this platform Eidos will be able to capitalize on BridgeBio’s global clinical development and regulatory expertise, its developing commercial infrastructure, and its broader capital base to reach more patients more effectively.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BridgeBio Pharma
Deal Size: $2,830.0 million Upfront Cash: $175.0 million
Deal Type: Merger October 05, 2020
Details:
Eidos is developing acoramidis (formerly AG10) as a potentially best-in-class treatment option for ATTR patients.
Lead Product(s): Acoramidis Hydrochloride
Therapeutic Area: Genetic Disease Product Name: AG10
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
